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Abstract
Background: Nerve growth factor (NGF) is a potent growth factor that plays a key role in neuronal cell differentiation
and may also play a role in hematopoietic differentiation. It has been shown that NGF induced synergistic action for the
colony formation of CD34 positive hematopoietic progenitor cells treated with macrophage-colony stimulating factor
(M-CSF or CSF-1), or stem cell factor (SCF). However, the exact role of NGF in hematopoietic system is unclear. It is also
not clear whether NGF mediated signals in hematopoietic cells are identical to those in neuronal cells.
Results: To study the signal transduction pathways induced by NGF treatment in hematopoietic cells, we utilized the
mastocytoma cell line HMC-1(V560G c-Kit) which expresses the NGF receptor, tropomyosin-receptor-kinase (Trk)A, as
well as the constitutively activated SCF receptor, V560G c-Kit, which can be inhibited completely by treatment with
the potent tyrosine kinase inhibitor imatinib mesylate (imatinib). NGF rescues HMC-1(V560G c-Kit) cells from imatinib
mediated cell death and promotes proliferation. To examine the NGF mediated proliferation and survival in these
cells, we compared the NGF mediated upregulated genes (30 and 120 min after stimulation) to the downregulated
genes by imatinib treatment (downregulation of c-Kit activity for 4 h) by transcriptome analysis. The following
conclusions can be drawn from the microarray data: Firstly, gene expression profiling reveals 50% overlap of genes
induced by NGF-TrkA with genes expressed downstream of V560G c-Kit. Secondly, NGF treatment does not enhance
expression of genes involved in immune related functions that were down regulated by imatinib treatment. Thirdly,
more than 55% of common upregulated genes are involved in cell proliferation and survival. Fourthly, we found
Kruppel-like factor (KLF) 2 and Smad family member 7 (SMAD7) as the NGF mediated novel downstream genes in
hematopoietic cells. Finally, the downregulation of KLF2 gene enhanced imatinib induced apoptosis.
Conclusion: NGF does not induce genes which are involved in immune related functions, but induces proliferation
and survival signals in HMC-1(V560G c-Kit) cells. Furthermore, the current data provide novel candidate genes, KLF2
and SMAD7 which are induced by NGF/TrkA activation in hematopoietic cells. Since the depletion of KLF2 causes
enhanced apoptosis of HMC-1(V560G c-Kit), KLF2 may play a role in the NGF mediated survival signal.
Background
Nerve growth factor (NGF) is a member of the family
of neurotrophins and is essential for the survival and dif-
ferentiation of neurons in central and peripheral nerve
systems [1]. The binding of NGF to its high affinity
receptor, tropomyosin-receptor-kinase(Trk)A, causes
activation of the receptor associated tyrosine kinase and
participates in the control of mitogenic, survival or differ-
entiation pathways. It has been suggested that NGF and
its receptor may also be involved in hematopoietic cell
development [2,3]. In those studies NGF induced syner-
gistic action for the colony formation of CD34 positive
hematopoietic progenitor cells treated with the macro-
phage colony stimulating factor (M-CSF, or CSF-1) [3],
or stem cell factor (SCF) [2]. However, the exact role of
TrkA in hematopoietic cell differentiation remains
unclear.
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role in hematopoietic stem cell and mast cell survival,
mitogenesis, proliferation, differentiation, adhesion, hom-
ing, migration, and functional activation. Despite diversity
in the mechanisms of their activation by growth factor
ligands [4], most receptor tyrosine kinases induce signals
through the same pathways to typically enhance prolifera-
tion and prolong viability. These pathways include activa-
tion of the Ras/Raf/Erk, activation of signal transducers
and activators of transcription (STATs), and phosphatidy-
linositol 3 kinase (PI3K). Indeed, c-Kit activation induces
all of these pathways, while activated TrkA induces Ras/
Raf/Erk, and PI3K pathways but does not cause tyrosine
phosphorylation of endogenous STATs [5,6], suggesting
that SCF and NGF not only induce common signal path-
ways, but also induce unique signal pathways. However,
the differences between a set of genes which are upregu-
lated by NGF and those upregulated by SCF in hemato-
poietic cells has not yet been studied.
The rat pheochromocytoma cell line, PC12, is one of
the most thoroughly established systems to study the
NGF mediated signal transduction pathway followed by
neuronal differentiation. Various studies have investi-
gated gene expression profiles in NGF-treated PC12
cells [7-14], however whether these upregulated genes
are similar to genes in the hematopoietic system is not
clear. Interestingly, leukemogenic mutant TrkA [5] does
not induce tumor formation, but induces the differentia-
tion of PC12 cells (Koch and Breyer, unpublished data),
suggesting that NGF/TrkA signaling is different in neu-
ronal and hematopoietic cells. We have previously
shown that NGF-TrkA signaling partially rescues TrkA
expressing Bcr-Abl transformed chronic myelogenous
leukemia (CML) cells, such as K562, and Meg-01, from
cell death induced by a potent inhibitor of Bcr-Abl tyro-
sine kinase, imatinib mesylate (imatinib). However, the
effects of NGF on imatinib treated CML cells are mod-
est. In the presence of NGF, the number of living K562
cells treated with imatinib increased by only 1.5-fold
within 4 days and Meg-01 cells did not grow, but just
survived for a longer period [15]. A dramatic effect of
NGF treatment was observed in oncogenic c-Kit
(V560G c-Kit) transformed human mastocytoma cells
(HMC-1 (V560G c-Kit))[16] which are also induced to
undergo apoptosis by treatment with imatinib. HMC-1
(V560G c-Kit) cells continue to grow nearly normally in
the presence of both imatinib and NGF [15].
In this paper, using HMC-1 (V560G c-Kit) cells we
compared NGF and SCF signaling in the same cell sys-
tem. HMC-1 [16] expresses the activated SCF receptor,
V560G and/or D816V c-Kit [17,18] and TrkA [19,20].
The kinase activity of V560G c-Kit can be inhibited com-
pletely by treatment with imatinib [21,22] and cells died
within 3 days. NGF rescues HMC-1 (V560G c-Kit) cells
from imatinib mediated cell death and promotes prolif-
eration [15], indicating that NGF can take over mitogenic
signaling in these cells. Therefore, we compared the NGF
mediated upregulated genes (30 and 120 min after stimu-
lation) to the downregulated genes by imatinib treatment
(downregulation of c-Kit for 4 h) by transcriptome analy-
sis. We found Kruppel-like factor (KLF) 2 and Smad
family member 7 (SMAD7) as the NGF mediated novel
down stream genes in hematopoietic cells and KLF2 may
be involved in NGF mediated survival of imatinib treated
cells.
Results
NGF rescues HMC-1 (V560G c-Kit) cells from imatinib
mediated cell death and promotes proliferation
To assess the biological effects of NGF on HMC-1(V560G
c-Kit) cells in the absence of c-Kit-mediated signal, we
treated the cells with 5 μM imatinib in the presence or
absence of 100 ng/ml NGF. Viable cells were counted 1, 2,
and 3 days after treatment using trypan blue cell exclusion
assay. In agreement with previous data [15], more than
95% cell death was observed within 48 h of treatment with
imatinib alone. In sharp contrast, HMC-1(V560G c-Kit)
cells treated with imatinib in the presence of NGF contin-
ued to proliferate even after 72 h at a rate almost similar
to untreated controls (Figure 1). In fact, NGF could sup-
port long-term survival (over 1 year) of these cells in the
presence of imatinib (Koch and Dutta, unpublished data).
In agreement with these data NGF treatment has been
shown to induce mitogenic signals in CD34 positive hema-
topoietic progenitor cells [2]. Interestingly, it has been
reported that the NGF stimulation induces the activation
Figure 1 NGF treatment rescues HMC-1 (V560G c-Kit) from
imatinib induced rapid cell death. Aliquots of 1 × 10
5 of HMC-1
(V560G c-Kit) cells were grown in medium containing 10% FCS with
or without NGF (100 ng/ml) in the presence or absence of imatinib
(5 μM) for 3 days. Cells were stained with 0.1% Trypan Blue and
living cells were counted using a Neubauer cell counting chamber.
Cell numbers are presented as the mean ± S.D. for three
independent experiments performed in triplicate.
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phorylation of STATs in PC12 cells [6], in promyeloid cell
line 32D [5] or in HMC-1 cells (Koch and Dutta, unpub-
lished data). On the other hand, STAT5 activation is
required for the maintenance of mast cells [23], suggesting
that NGF may induce unknown signals for the mainte-
nance of HMC-1(V560G c-Kit) cells without STATs sig-
naling. We next analyzed the gene profile induced by NGF
treatment of HMC-1(V560G c-Kit) cells. To understand
how NGF-TrkA activation counteracts the effect of c-Kit
inhibition and promotes survival in HMC-1(V560G c-Kit)
cells we performed gene expression profiling using a high
density microarray technique employing the “Whole
Human Genome Microarray” (G4112F, ID 014850, Agilent
Technologies) that contains 45,015 probes. First, we deter-
mined the genes which were regulated as a result of c-Kit
inhibition by comparing untreated HMC-1(V560G c-Kit)
cells in serum free medium with cells after addition of
5 μM imatinib for 4 h. Second, we studied changes in gene
expression caused by the addition of NGF (100 ng/ml) for
30 min (immediate early genes) and 2 h (delayed early
genes) to the imatinib treated cells. Based on the filtering
criteria mentioned in the methods section, 524 genes of
known identities were downregulated and 328 genes were
upregulated by treatment with imatinib, with expression
ratios ranging from 2 to 45-fold and 2 to 10-fold, respec-
tively. Twenty one genes of known identities were found
induced after 30 min and 121 genes after 2 h of NGF sti-
mulation following 4 h of imatinib treatment, with fold
induction values ranging from 2 to 94- and 2 to 30-fold,
respectively. Furthermore, NGF treatment repressed one
gene after 30 min and seven genes after 2 h in imatinib
treated cells.
NGF induced immediate and delayed early genes in
imatinib treated HMC-1(V560G c-Kit) cells including
several known NGF responsive immediate early genes
such as the early growth response (EGR) family EGR1, 2
and 4, c-FOS, and JUNB being upregulated after 30 min
of NGF treatment, followed by induction of delayed early
g e n e ss u c ha sN G F I - Ab i n d i ng protein 2 (NAB2), hairy
and enhancer of split, (Drosophila) (HES1), Kruppel-like
factor (KLF)10, and activating transcription factors 3
(ATF3) after 2 h.
Prominently, EGR1 (or NGF1-A), first discovered as a
NGF responsive gene in PC12 cells, was induced more
than 90-fold within 30 min of TrkA activation providing
an initial validation for our array [7]. To gain insight
into the potential mechanism by which NGF can over-
come imatinib induced apoptosis we focused our further
investigation on the comparison of genes that were
downregulated by imatinib and up-regulated by NGF
treatment for 2 h. To derive a biological meaning from
the individual lists of V560G c-Kit and NGF-TrkA-
modulated genes, we uploaded these lists to Ingenuity
Pathways Analysis (IPA, Ingenuity Systems, Mountain
View, CA) application for biological function and path-
way analysis. Out of a total of 524 genes modulated by
imatinib treatment 510 genes mapped to the IPA knowl-
edge database with 428 genes for functions/pathways
analysis. Out of 117 NGF induced genes accepted by the
IPA knowledge database (Table 1), 106 mapped for
functions/pathways analysis. A comparison of the two
gene lists revealed a common set of 58 genes out of 117
NGF upregulated genes (Table 1) that were also down-
modulated by imatinib (Figure 2). This suggests that
NGF-TrkA signaling regulates many genes the expres-
sion of which are also regulated by V560G c-Kit in
HMC-1 cells.
NGF-TrkA activation does not enhance expression of
genes involved in immune related functions that were
downregulated by imatinib treatment
Since the expression of 452 genes out of 510 genes
which were downregulated by imatinib treatment for
4 h was not restored by the stimulation with NGF for
2 h (Figure 2), we next analyzed the two datasets using
PANTHER (Protein ANalysis THrough Evolutionary
Relationships) protein class analysis which measures the
significance of certain functional categories among these
targets by their enrichment relative to the total numbers
in their respective categories. As shown in Table 2,
immune response component genes such as cytokines
and cytokine receptors genes were significantly downre-
gulated (p = 2.45E-06 and 6.65E-04, respectively) by
imatinib treatment. In contrast, NGF-TrkA does not acti-
vate receptor genes significantly (Table 2, NS). In addi-
tion, NGF-TrkA activated cytokine genes (p = 3.33E-03)
but drastically fewer genes than c-Kit mediated gene
modulation (Table 2). These data suggest that NGF can
take over the proliferation signal but not immune related
function induced by c-Kit.
More than 67% of NGF-TrkA upregulated genes are
involved in cell survival and proliferation
We next analyzed genes which are upregulated by NGF-
TrkA signaling by IPA analysis. Significantly, over 67% of
upregulated genes are involved in survival and prolifera-
tion (Table 3). Although the immediate-early response
genes, such as EGR4, c-FOS, or FOSB are also down-
stream of c-Kit signaling, these genes are not constitu-
tively expressing. Therefore, several c-Kit inducible genes
were not downregulated by imatinib treatment. To con-
firm the micro array data, we performed quantitative
reverse-transcriptase polymerase chain reaction (qRT-
PCR) to examine the relative expression level of c-FOS,
JUNB, EGR1, and c-MYC. HMC-1(V560G c-Kit) cells
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Symbol Gene
accession ID
Description Fold
change
CYTOKINES
CLCF1 NM_013246 cardiotrophin-like cytokine factor 1 2.6
FASLG NM_000639 Fas ligand (TNF superfamily, member 6) 3.0
IL1B NM_000576 interleukin 1, beta 2.2
LIF NM_002309 leukemia inhibitory factor (cholinergic differentiation factor) 2.4
LTB NM_002341 lymphotoxin beta (TNF superfamily, member 3) 2.2
GROWTH FACTOR
GDF15 NM_004864 growth differentiation factor 15 3.2
ENZYMES
ARL5B NM_178815 ADP-ribosylation factor-like 5B 3.1
B3GALNT2 NM_152490 beta-1,3-N-acetylgalactosaminyltransferase 2 2.8
CYCS NM_018947 cytochrome c, somatic 2.6
GALNT4 NM_003774 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) 3.2
GEM NM_005261 GTP binding protein overexpressed in skeletal muscle 2.9
LFNG NM_001040167 LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 2.5
PAICS NM_006452 phosphoribosylaminoimidazole carboxylase, phosphoribosylaminoimidazole succinocarboxamide synthetase 2.9
RRAD NM_004165 Ras-related associated with diabetes 2.5
TEP1 NM_007110 telomerase-associated protein 1 3.8
UBE2E1 NM_152653 ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) 4.2
KINASES
AATK AK131529 cDNA FLJ16758 fis, clone BRACE3038687, moderately similar to Homo sapiens apoptosis-associated tyrosine
kinase (AATK)
2.5
PANK2 AL713654 Homo sapiens mRNA; cDNA DKFZp547J0513 (from clone DKFZp547J0513). 2.2
PLK3 NM_004073 polo-like kinase 3 (Drosophila) 5.1
PRKAR2A NM_004157 protein kinase, cAMP-dependent, regulatory, type II, alpha 3.4
SGK1 NM_005627 serum/glucocorticoid regulated kinase 2.3
TRIB1 NM_025195 tribbles homolog 1 (Drosophila) 2.8
LIGAND DEPENDENT NUCLEAR RECEPTOR
NR4A1 NM_002135 nuclear receptor subfamily 4, group A, member 1 4.7
NR4A2 NM_006186 nuclear receptor subfamily 4, group A, member 2 2.8
NR4A3 NM_006981 nuclear receptor subfamily 4, group A, member 3 2.6
G-PROTEIN COUPLED RECEPTORS
CXCR4 NM_001008540 chemokine (C-X-C motif) receptor 4 (CXCR4), transcript variant 1 2.0
HRH1 NM_000861 histamine receptor H1 2.1
PEPTIDASE
CTSZ NM_001336 cathepsin Z 3.0
TRANSCRIPTON REGULATOR
ACTN2 NM_001103 actinin, alpha 2 2.5
ARNTL2 NM_020183 aryl hydrocarbon receptor nuclear translocator-like 2 2.2
ATF3 NM_004024 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 2 2.9
AXUD1 NM_033027 AXIN1 up-regulated 1 (AXUD1) 2.5
EGR1 NM_001964 early growth response 1 29.6
EGR2 NM_000399 early growth response 2 13.6
EGR3 NM_004430 early growth response 3 22.8
EGR4 NM_001965 early growth response 4 5.2
ETV5 NM_004454 ets variant 5 3.2
FOS NM_005252 FBJ murine osteosarcoma viral oncogene homolog 3.5
FOSB NM_006732 Homo sapiens FBJ murine osteosarcoma viral oncogene homolog B (FOSB) 3.7
FOSL1 NM_005438 FOS-like antigen 1 4.7
FOSL2 NM_005253 FOS-like antigen 2 2.5
HES1 NM_005524 hairy and enhancer of split 1, (Drosophila) 3.4
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HOXB8 NM_024016 homeobox B8 14.1
JUNB NM_002229 jun B proto-oncogene 2.1
KLF10 NM_005655 Kruppel-like factor 10 (KLF10), transcript variant 1 7.5
KLF2 NM_016270 Kruppel-like factor 2 (lung) 2.9
MAFF NM_012323 v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) (MAFF), transcript variant 1 2.6
MYC NM_002467 v-myc myelocytomatosis viral oncogene homolog (avian) 4.1
NAB2 NM_005967 NGFI-A binding protein 2 (EGR1 binding protein 2) 2.2
NOC2L NM_015658 nucleolar complex associated 2 homolog (S. cerevisiae) 2.6
PBX2 NM_002586 pre-B-cell leukemia homeobox 2 2.7
POLR3E AB040885 mRNA for KIAA1452 protein, partial cds. 4.0
RYBP NM_012234 RING1 and YY1 binding protein 2.3
SF1 NM_004630 splicing factor 1 6.4
SKIL NM_005414 SKI-like (SKIL) 3.1
SMAD7 NM_005904 SMAD family member 7 2.2
ST18 NM_014682 suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein) 2.0
ZFP36 NM_003407 zinc finger protein 36, C3H type, homolog (mouse) 2.3
ZFP36L1 NM_004928 zinc finger protein 36, C3H type-like 1 2.6
TRANSPORTERS
AP1S1 NM_057089 adaptor-related protein complex 1, sigma 1 subunit (AP1S1), transcript variant 2 2.3
APOL6 NM_030641 apolipoprotein L, 6 3.9
GGA1 NM_001001560 golgi-associated, gamma adaptin ear containing, ARF binding protein 1 3.1
MCL1 NM_021960 myeloid cell leukemia sequence 1 (BCL2-related) 2.3
SLC2A14 BC060766 solute carrier family 2 (facilitated glucose transporter), member 14, mRNA (cDNA clone MGC:71510
IMAGE:5297510), complete cds. [BC060766]
2.9
SLC2A3 NM_006931 solute carrier family 2 (facilitated glucose transporter), member 3 2.5
STX1A NM_004603 syntaxin 1A (brain) (STX1A) 2.5
TMC6 NM_152453 transmembrane and coiled-coil domains 5 (TMCO5) 3.3
PHOSPHATASES
DUSP4 NM_001394 dual specificity phosphatase 4 2.7
DUSP5 NM_004419 dual specificity phosphatase 5 2.1
DUSP6 NM_001946 dual specificity phosphatase 6 19.9
EYA4 NM_004100 eyes absent homolog 4 (Drosophila) 2.1
OTHERS
ADM NM_001124 adrenomedullin 2.4
CASC5 NM_170589 cancer susceptibility candidate 5 (CASC5), transcript variant 1 3.3
CCDC71 NM_022903 coiled-coil domain containing 71 3.1
CCND1 NM_053056 cyclin D1 8.3
CDKN1A NM_000389 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2.5
CLN8 NM_018941 ceroid-lipofuscinosis, neuronal 8 (epilepsy, progressive with mental retardation) 2.2
PSCD4 NM_013385 pleckstrin homology, Sec7 and coiled-coil domains 4 (PSCD4), 3.4
DDIT4 NM_019058 Homo sapiens DNA-damage-inducible transcript 4 (DDIT4), 2.4
FAM40B NM_020704 family with sequence similarity 40, member B (FAM40B) 4.4
FBXL17 BC018548 F-box and leucine-rich repeat protein 17, mRNA (cDNA clone IMAGE:4215262), partial cds. [BC018548] 5.1
FST NM_013409 follistatin 2.2
GNL3L NM_019067 guanine nucleotide binding protein-like 3 (nucleolar)-like 2.3
GOLGA1 NM_002077 golgin A1 3.7
HNRNPA0 NM_006805 heterogeneous nuclear ribonucleoprotein A0 (HNRPA0) 3.0
IER2 NM_004907 immediate early response 2 2.5
IER3 NM_003897 immediate early response 3 9.2
LMNB1 NM_005573 lamin B1 3.0
LRRC8B NM_015350 leucine rich repeat containing 8 family, member B (LRRC8B) 2.0
LUZP1 NM_033631 leucine zipper protein 1 (LUZP1) 2.8
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Page 5 of 14were incubated without serum for 17 h and were then
treated with imatinib (5 μM) for 4 h. Cells were stimu-
l a t e dw i t hN G Ff o r3 0a n d1 2 0m i n .A l ls a m p l e sw e r e
standardized by expression level of glucuronidase beta
(GUSB) mRNA. In agreement with the micro array data,
qRT-PCR analysis revealed that immediate-early response
genes, such as c-FOS (Figure 3A, 33 fold) JUNB (Figure
3B, 3-4.4 fold), and EGR1 (Figure 3C, 68-80 fold), were
upregulated upon stimulation with NGF compared to
expression level in untreated HMC-1(V560G c-Kit) cells.
Standardization of RNA level using a GUSB probe was
c o n f i r m e db yaG A P D Hp r o b e .T h er e l a t i v ee x p r e s s i o n
level of each sample was comparable (Figure 3D). c-MYC
expression was also upregulated upon stimulation with
NGF in imatinib treated cells in the absence of serum,
however, its expression level was lower than that in
Table 1 List of gene set regulated by NGF in HMC-1 (V560G c-Kit) cells (Continued)
MALAT1 NR_002819 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) 4.9
MED18 NM_017638 mediator of RNA polymerase II transcription, subunit 18 homolog (S. cerevisiae) (MED18) 15.0
METTL7A NM_014033 methyltransferase like 7A 2.6
MYEOV NM_138768 myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas) 3.7
NUP188 BC005407 nucleoporin 188kDa, mRNA (cDNA clone IMAGE:3461492), partial cds. [BC005407] 2.8
PER2 NM_022817 period homolog 2 (Drosophila) 2.5
PHLDA1 NM_007350 pleckstrin homology-like domain, family A, member 1 9.7
PHLDA2 NM_003311 pleckstrin homology-like domain, family A, member 2 2.3
PMAIP1 NM_021127 phorbol-12-myristate-13-acetate-induced protein 1 3.6
PRNP NM_000311 prion protein 3.2
RAPGEF5 D87467 mRNA for KIAA0277 gene, partial cds. [D87467] 18.5
RNF125 NM_017831 ring finger protein 125 5.1
RPL23 BC034378 ribosomal protein L23, mRNA (cDNA clone MGC:34067 IMAGE:5186030), complete cds. [BC034378] 2.3
SERPINE1 NM_000602 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 3.3
SH2B3 NM_005475 SH2B adaptor protein 3 2.4
SH2D2A NM_003975 SH2 domain protein 2A (SH2D2A) 2.1
SPRED1 NM_152594 sprouty-related, EVH1 domain containing 1 6.4
SPRED2 NM_181784 sprouty-related, EVH1 domain containing 2 3.1
SPRY2 NM_005842 sprouty homolog 2 (Drosophila) 6.6
TMEM49 NM_030938 transmembrane protein 49 7.3
TMEPAI NM_020182 transmembrane, prostate androgen induced RNA (TMEPAI), transcript variant 1 4.2
TNFRSF12A NM_016639 tumor necrosis factor receptor superfamily, member 12A 4.8
UBQLN1 NM_013438 ubiquilin 1 4.6
ZC3H7B NM_017590 zinc finger CCCH-type containing 7B 3.9
ZCCHC2 NM_017742 zinc finger, CCHC domain containing 2 2.2
ZNF295 NM_020727 zinc finger protein 295 (ZNF295) 2.8
VIL2 NM_003379 villin 2 (ezrin) (VIL2) 2.3
Figure 2 Venn diagram of the number of genes which are
upregulated by NGF treatment or downregulated by imatinib
treatment. Fifty eight genes from the two data sets overlap.
Table 2 PANTHER analyses of c-Kit (downregulated genes
by imatinib treatment) versus NGF-regulated genes
which are involved in immune related function in HMC-1
(V560G c-Kit) cells (selected)
PANTHER Protein Class V560G c-KIT
(P-value)
NGF-TrkA
(P-value)
Cytokine 2.45E-06 3.33E-03
Cytokine/interleukin
superfamily
6.74E-05 2.15E-02
Receptor 1.17E-04 NS
Receptor/cytokine receptor 6.65E-04 NS
receptor /type I cytokine
receptor
3.81E-03 NS
Esterase 2.10E-03 NS
NS: not significant.
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examine whether high c-MYC expression in untreated
cells is due to the activated c-Kit kinase and/or serum
which may contain activation factor(s) of the c-MYC
gene, we performed c-MYC specific qRT-PCR in the pre-
sence of serum with imatinib and/or NGF (120 min).
Imatinib suppressed c-MYC expression about 70% even
in the presence of serum, suggesting that activated c-Kit
(V560G) induces c-MYC expression. However, in the
presence of serum, NGF induces c-MYC expression 2-
fold more than in the absence of serum, suggesting that
serum and c-Kit or TrkA tyrosine kinase synergistically
induce c-MYC expression (Figure 3E).
Furthermore, 32 genes, including c-MYC, EGR1,
EGR2, HES1, and KLF2 of 58 genes that were downmo-
dulated by imatinib and upregulated upon stimulation
with NGF are involved in survival and proliferation, sug-
gesting that NGF/TrkA signaling may take over the sur-
vival and/or mitogenic signal in the imatinib treated
HMC-1(V560G c-Kit) cells using these genes.
Table 3 Ingenuity biological function analyses of NGF regulated genes in HMC-1 (V560G c-Kit) cells (selected)
CATEGORY
sub category or function
annotation
P-value NGF induced molecules
1. CELL DEATH
Apoptosis 1.71E-15 AATK, ADM, ATF3, CCND1, CDKN1A, CLCF1, CLN8, CXCR4, CYCS, DDIT4, DUSP4, DUSP6, EGR1, EGR2,
EGR3, EGR4, EZR, FASLG, FOS, FOSB, FOSL1, FST, GDF15, HES1, IER3, IL1B, KLF2, KLF10, LIF, LMNB1, LTB,
MCL1, MYC, NOC2L, NR4A1, NR4A2, NR4A3, PHLDA1, PHLDA2, PLK3, PMAIP1, PMEPA1, PRNP, RYBP,
SERPINE1, SGK1, SKIL, SLC2A3, SMAD7, SPRY2, STX1A, TNFRSF12A, TRIB1, ZFP36
Cell survival 1.61E-04 CCND1, CDKN1A, CLCF1, DUSP5, DUSP6, EGR3, FASLG, GDF15, HES1, IL1B, LIF, MCL1, MYC, NR4A1, PRNP,
SERPINE1, SGK1, ZFP36
2. CELL GROWTH AND PROLIFERATION
Growth 4.16E-12 ADM, ARNTL2, ATF3, CCND1, CDKN1A, CXCR4, DUSP5, DUSP6, EGR1, EGR2, EZR, FASLG, FOS, FOSL1, FST,
GDF15, GEM, GGA1, HNRNPA0, IER3, IL1B, JUNB, KLF2, KLF10, LIF, MAFF, MCL1, MYC, NR4A2, NR4A3,
PHLDA1, PHLDA2, PMEPA1, PRNP, RRAD, SERPINE1, SF1, SGK1, SH2B3, SKIL, SMAD7, SPRY2, TMEM49,
TNFRSF12A
Proliferation 3.46E-10 ADM, CCND1, CDKN1A, CLCF1, CTSZ, CXCR4, EGR1, EGR2, EGR3, FASLG, FOS, FOSB, FOSL1, FOSL2, FST,
GDF15, HES1, HRH1, IER3, IL1B, JUNB, KLF2, KLF10, LIF, MYC, NAB2, NR4A1, NR4A3, PMAIP1, PRNP,
SERPINE1, SF1, SH2B3, SH2D2A, SKIL, SMAD7, SPRED1, SPRY2, TNFRSF12A, TRIB1, ZFP36, ZFP36L1
3. CELL DEVELOPMENT
Development of blood
cells
1.24E-11 ADM, CCND1, CDKN1A, CLCF1, CXCR4, DUSP5, EGR1, EGR2, EGR3, EZR, FASLG, FOS, FOSL1, HRH1, IER3,
IL1B, JUNB, KLF2, KLF10, LFNG, LIF, LTB, MYC, NR4A1, PRNP, SH2B3, SH2D2A, SMAD7, SPRED2,
TNFRSF12A, ZFP36
Development of tumor
cell lines
1.20E-10 ADM, ATF3, CCND1, CDKN1A, CXCR4, DUSP5, EGR1, EGR2, FOS, FOSL1, FST, GDF15, GEM, HES1, IER3,
IL1B, KLF2, LIF, MCL1, MYC, NAB2, NR4A2, PMEPA1, PRNP, RRAD, SERPINE1, SMAD7, SPRY2, TMEM49
Differentiation of cells 5.57E-09 ATF3, CCND1, CDKN1A, CLCF1, CXCR4, DUSP5, EGR1, EGR2, EGR3, FASLG, FOS, FOSL1, FOSL2, FST, HES1,
HRH1, IL1B, JUNB, KLF10, LIF, MAFF, MCL1, MYC, NAB2, NR4A1, NR4A2, NR4A3, PRNP, SH2B3, SKIL,
SMAD7, SPRED1, SPRED2, SPRY2, TNFRSF12A, ZFP36
Haematopoesis 2.82E-05 ATF3, CCND1, CDKN1A, CLCF1, CXCR4, DUSP5, EGR1, EGR2, EGR3, FASLG, FOS, FOSL1, FOSL2, FST, HES1,
HRH1, IL1B, JUNB, KLF10, LIF, MAFF, MCL1, MYC, NAB2, NR4A1, NR4A2, NR4A3, PRNP, SH2B3, SKIL,
SMAD7, SPRED1, SPRED2, SPRY2, TNFRSF12A, ZFP36
Maturation of cells 1.73E-05 CCND1, CDKN1A, EGR1, FASLG, FOS, HES1, IL1B, LFNG, LIF, MYC, NR4A2, PRNP
4. CELL MORPHOLOGY
Morphology 8.65E-10 ADM, ATF3, CCND1, CDKN1A, EGR1, EZR, FOS, FOSL1, GDF15, GEM, JUNB, KLF2, LIF, MYC, PLK3,
SERPINE1
Cell size 5.16E-04 CCND1, CDKN1A, KLF2, MYC
5. CELLULAR FUNCTION AND MAINTAINANCE
T cell development 2.19E-09 CCND1, CDKN1A, CXCR4, EGR1, EGR2, EGR3, EZR, FASLG, FOS, IER3, IL1B, JUNB, KLF2, KLF10, LFNG, LIF,
LTB, MYC, NR4A1, PRNP, SH2D2A, SMAD7
Cell death of T
lymphocytes
8.90E-09 CDKN1A, CXCR4, EGR1, EGR3, EZR, FASLG, FOS, IER3, IL1B, KLF2, MYC, NR4A1, SH2D2A, SMAD7
6. GENE EXPRESSION
Transcription 3.62E-08 ATF3, CCND1, CDKN1A, CSRNP1, DUSP4, EGR1, EGR2, EGR4, ETV5, FASLG, FOS, FOSB, FOSL1, FOSL2, FST,
HES1, IL1B, JUNB, KLF2, KLF10, LIF, MAFF, MYC, NAB2, NOC2L, NR4A1, NR4A2, NR4A3, PBX2, PER2, RYBP,
SGK1, SH2B3, SH2D2A, SKIL, SMAD7, ST18, ZFP36
Gene activation 7.79E-06 CCND1, EGR2, FOS, FOSB, FOSL1, FOSL2, KLF2, LIF, MYC, NR4A1, NR4A2
Gene repression 5.37E-05 FOS, FOSB, HES1, KLF10, MYC, NR4A2
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Page 7 of 14Figure 3 Quantitative RT-PCR analysis of c-FOS, JUNB, EGR1 and c-MYC induced by NGF in HMC-1 (V560G c-Kit) cells. HMC-1 (V560G
c-Kit) cells were either incubated with serum or in serum free medium for 17 h, then treated without or with imatinib (5 μM) for 4 h prior to
stimulation without or with NGF (100 ng/ml) for 30 and 120 min. Total RNA was isolated and, after reverse transcription, was examined by
qRT-PCR using (A) c-FOS, (B) JUNB, (C) EGR1, (D) GAPDH and (E) c-MYC specific probes. Differences in mRNA expression levels are depicted as
fold change values. Expression levels, in each case relative to GUSB as housekeeping gene, were normalized to gene expression in HMC-1
(V560G c-Kit) cells grown in serum containing medium. GAPDH served as a non-regulated control gene. Average values from three independent
PCR reactions + standard error of the mean (SEM) are shown.
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Page 8 of 14Novel target genes, KLF2, and SMAD7 which were
induced by NGF-TrkA signaling are involved in anti
apoptosis signal in hematopoietic cell system
Expression profiling of NGF-TrkA induced genes is well
documented in neuronal cell systems [7-13]. However,
there is no information about profiles of genes induced by
NGF-TrkA signaling in a hematopoietic cell system. We
therefore compared our upregulated genes to known NGF
targets in neuronal cells. Several genes, such as the
recently demonstrated ATF3, KLF10, and v-maf muscu-
loaponeurotic fibrosarcoma oncogene family protein
F (MAFF) [7] were found to be induced in our array.
In addition to the above, we show for the first time the
upregulation of potential novel TrkA target genes such as
KLF2, SMAD7, and Homeobox members, HOXB8 and
PBX2, upon NGF stimulation in HMC-1(V560G c-Kit)
cells. Since it has been shown that an immediate early
gene product, KLF2 activates SMAD7 expression [24], we
examined the upregulation of KLF2, SMAD7 and EGR1
by RT-PCR (Figure 4). In agreement with array data, KLF2
was upregulated within 30 min similar to the EGR1 gene,
however, SMAD7 was upregulated in 2 h (Figure 4A),
Figure 4 KLF2 and SMAD7 genes were upregulated by stimulation with SCF or NGF. A: HMC-1 (V560G c-Kit) cells were either incubated
with serum (serum) or in serum free medium for 17 h, then treated without (-) or with (+) imatinib (5 μM) for 4 h prior to stimulation without
(-) or with SCF (100 ng/ml) or NGF (100 ng/ml) for 30 (30) and 120 min (120). Total RNA was isolated and, after reverse transcription with Oligo
dT-primers, cDNA was analyzed by semi-quantitative PCR for expression of EGR1, KLF2, SMAD7 and actin (ACTB). Water (H2O) and RNA (RNA)
serve as negative controls. bp: base pairs of the DNA marker. B: Expression of KLF2 was quantified using TaqMan-PCR as in figure 3. Relative
expression levels compared to GUSB were normalized to gene expression in serum-starved HMC-1(V560G c-Kit) cells. Average values from six
independent PCR reactions + SEM are shown.
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Page 9 of 14suggesting that KLF2 may be the direct target gene of
NGF/TrkA signaling, but not SMAD7. We next asked
whether KLF2 and SMAD7 are targets of c-Kit signaling.
Since oncogenic c-Kit (V560G) is not fully activated, SCF
treatment is able to induce further upregulation of c-Kit
mediated signaling [25]. HMC-1(V560G c-Kit) cells were
grown in the absence of serum for 17 h, and were then sti-
mulated with SCF (100ng/ml). The expression of KLF2,
SMAD7 and EGR1 was then examined by RT-PCR. All
three genes were upregulated by stimulation with SCF
(Figure 4A). It should be noted that KLF2 and SMAD7 are
also novel target genes for c-Kit signaling. To further con-
firm these data, we performed KLF2 specific qRT-PCR
showing that serum starvation down-regulates KLF2
expression about 5-fold. However, upon stimulation with
SCF or NGF in the absence of serum, within 30 min the
KLF2 gene was upregulated 24-fold and 14-fold, respec-
tively (Figure 4B). KLF2 is known to regulate self renewal
and block the differentiation in embryo stem cells [26-28],
suggesting that NGF/TrkA associates with a novel func-
tion other than neuronal differentiation. To examine
whether KLF2 participates in the survival and proliferation
signal induced by NGF, the KLF2 gene was downregulated
by KLF2 specific siRNA in HMC-1(V560G c-Kit) cells.
Two days after treatment of HMC-1 (V560G c-Kit) with
KLF2 specific siRNA, the expression level of KLF2
declined to 26% (Figure 5A). The transient knockdown of
KLF2 in HMC-1(V560G c-Kit) cells did not change the
growth rate within 3 days after transfection under normal
condition or in the presence of imatinib and NGF. We
next examined whether KLF2 plays a role as a survival sig-
nal in imatinib treated HMC-1 (V560G c-Kit) cells. We
began by examining caspase 3 cleavage. Cleaved caspase 3
was observed only 9 h after imatinib treatment in control
siRNA treated cells, whereas in KLF2 specific siRNA trea-
ted cells caspase 3 was cleaved within 6 h (Figure 5B).
Furthermore, to assess the degree of apoptosis, sister
culture cells were stained by an in situ cell death detec-
tion kit (Roche, Mannheim, Germany) for terminal
deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL). In agreement with data obtained
from caspase 3 cleavage, TUNEL positive cells appeared
within 6 h after imatinib treatment in both KLF2 speci-
fic siRNA and control siRNA treated cells. However,
numbers of TUNEL positive cells increased significantly
faster in KLF2 siRNA treated cells than in control
siRNA transfected cells 6 (p = 0.008), 9 (p = 0.009) and
15 h (p = 0.0005) after imatinib treatment (Figure 5C).
Since KLF2 specific siRNA transfectants still grow in
the presence of NGF and imatinib, additional survival
signals may be mediated by NGF treatment. However,
our data strongly suggest that KLF2 is involved in an
anti-apoptosis signal.
Discussion
Cell differentiation and self-renewal are paralleled by a
timely, ordered expression of a set of cytokines, growth
factors and corresponding receptors. Many members of
receptor tyrosine kinase family have emerged as key reg-
ulators of these critical cellular processes [4,29,30].
Humans have 58 known receptor tyrosine kinases,
which fall into 20 subfamilies. Despite differences in
structure, many of tyrosine kinases signal through the
same pathways to typically enhance proliferation and
prolong viability. These pathways include activation of
the Ras/Raf/Erk, STATs and PI3K. These facts raised
the question of whether each receptor tyrosine kinase is
associated with a similar signaling potential, regulated
by different expression patterns in different cell types, or
whether each tyrosine kinase exhibits a unique signaling
pathway.
It has previously been shown that TrkA and c-Kit are
co-expressed in mast cells and hematopoietic CD34
positive cells. The treatment of CD34 positive cells with
NGF showed the synergistic effects with the SCF treat-
ment on colony formation. For mast cell culture
in vitro, bone marrow cells are cultivated for 4-6 weeks
in the presence of SCF, interleukin (IL) 3 and IL4 [31].
We examined whether mouse primary mast cells can
survive in the presence of NGF, or NGF and IL3/IL4 in
the absence of SCF. Under these conditions mouse mast
cells did not survive in the absence of SCF. These data
suggest that NGF does not assume the role of SCF in
normal mast cells. According to PANTHER analysis
[32,33], the difference of gene upregulation of cytokines,
growth factors, and their receptors between SCF and
NGF stimulation is significant, suggesting that upregula-
tion of cytokines and their receptors play a role in survi-
v a lo fn o r m a lm a s tc e l l s .I na greement with these data,
few genes encoding cytokines/their receptors in PC12
cells were upregulated 24 h after NGF treatment [9],
suggesting that NGF poorly induces cytokine and
growth factor genes in different cell types.
It has been shown that STAT5 is required for c-Kit
mediated mast cell survival and differentiation [23].
Although NGF does not induce tyrosine phosphorylation
of STATs, HMC-1(V560G c-Kit) cells survive by NGF sti-
mulation without c-Kit signaling. Thereby our array data
provide novel candidate genes, KLF2, SMAD7, PBX2, and
HOXB8 which are induced by NGF/TrkA activation in
hematopoietic cells, and have not been reported as NGF
target genes in the PC12 cell system [7-14]. On the other
hand, another known target gene of NGF treatment in
PC12 cells, wingless-related MMTV integration site 7B
(Wnt7b) [14] was not upregulated by NGF treatment in
HMC-1 (V560G c-Kit) cells, suggesting that Wnt7b may
be a specific target gene for NGF signaling in neuronal
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Page 10 of 14cells. These data indicate that most NGF upregulated
genes were common, but some of them may be cell-type
specific. However, we cannot presently rule out the possi-
bility that the difference of upregulated genes is due to
differences between human (HMC-1) and rat (PC12) cells.
Interestingly, KLF2, SMAD7, PBX2, and HOXB8 are
suggested to be involved in self-renewal or in anti
differentiation signal of stem cells or hematopoietic
stem cells [26,34-37]. We show here that KLF2 modu-
lates imatinib-mediate apoptosis. Along the same line, it
has been shown that KLF2-deficient T cells had a spon-
taneously activated phenotype and died rapidly from
Fas-ligand-induced apoptosis [38], and induction of
KLF2 expression corresponded with long-term T cell
Figure 5 Knockdown of KLF2 modulates the imatinib induced apoptosis. A: HMC-1 cells were transfected with control siRNA or siRNA
directed against KLF2 (KLF2 siRNA). 48 h after transfection, cDNA of untransfected (-) and transfected cells (control siRNA and KLF2 siRNA) was
prepared and analyzed for expression of KLF2 and actin (ACTB) by semi-quantitative RT-PCR. KLF2 bands were quantified using TINA2.0 software
and were normalized to actin. B: SiRNA transfected cells as in A were treated with imatinib (5 μM) for the indicated times. Every 3 h, whole cell
lysates were prepared for detection of cleaved caspase-3 (cl. Caspase 3) and GAPDH by immunoblot. C: Cells were transfected and treated with
imatinib as in B. At the indicated times after imatinib treatment, cells were fixed with paraformaldehyde and apoptotic cells were detected by
TUNEL staining. Observations from different fields in the microscope (between 300 and 700 cells per experimental condition) are depicted as the
mean +/- SD of % TUNEL positive cells. Student’s t-test was applied to describe the significance of differences between cells treated with control
siRNA and KLF2 siRNA. P-values ≤ 0.05 were considered as significant and are indicated above the corresponding columns. bp: base pairs of the
DNA marker. MW: molecular weight.
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Page 11 of 14survival [39], suggesting that KLF2 plays a role in T cell
survival. Furthermore, KLF2-/- embryos have a signifi-
cantly increased number of primitive erythroid cells
undergoing apoptotic cell death. These data suggest that
the upregulation of the KLF2 gene induced by the sti-
mulation with NGF plays a role in the survival signal in
imatinib treated HMC-1(V560G c-Kit) cells.
Conclusion
We compared the signaling of two structurally and
functionally diverse receptor tyrosine kinases, c-Kit and
TrkA, in hematopoietic cells. The c-Kit activation
induces cytokines and their receptors, but TrkA does
not, suggesting that the part of the signal pathways
induced by the two receptors is different. However,
TrkA is able to induce common novel downstream tar-
gets such as KLF2 and SMAD7 which has not been
reported in the neuronal system, indicating that NGF
induces genes which are involved in stem cell mainte-
nance similar to c-Kit signaling in hematopoietic cells.
Furthermore, upregulation of KLF2 may be involved in
NGF mediated survival of imatinib treated cells.
Methods
Cell lines
HMC-1(V560G c-Kit) [16] were grown in RPMI1640
medium supplemented with 10-20% (v/v) fetal calf
serum (FCS). The presence of V560G mutation and the
absence of 816 mutation in c-Kit was confirmed by
sequencing.
Viability assay
HMC-1(V560G c-Kit) cells were grown in medium con-
taining 10% FCS in the presence of 5 μMi m a t i n i b
(kindly provided by Novartis, Basel, Switzerland) and/or
100 ng/ml human recombinant NGF (PeproTech Inc.,
Rocky Hill, NJ). Cells were counted in a Neubauer
chamber using 0.1% Trypan Blue (Sigma-Aldrich Che-
mie GmbH, Steinheim, Germany).
TUNEL assay
To assess the degree of apoptosis, an in situ cell death
detection kit (Roche, Mannheim, Germany) was used
for terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) staining.
Growth factor stimulation, and RNA-isolation
Cells were serum starved for 17 h, then treated with
dimethyl sulfoxide (DMSO) or 5 μM imatinib for 4 hours
prior to stimulation with 100 ng/ml mouse recombinant
SCF (PeproTech Inc.) or NGF, respectively. After 30 or
120 min the stimulation was stopped in ice-cold PBS.
RNA was isolated from growth factor treated or
untreated HMC-1(V560G c-Kit) cells using RNeasy Mini
kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. Residual DNA contamination was
removed with DNAseI (Invitrogen GmbH, Darmstadt,
Germany) according to the manufacturer’s recommenda-
tions, and the RNA was again purified with RNeasy Mini
kit (Qiagen).
Microarray analysis
The “Whole Human Genome Microarray” (G4112F, ID
014850, Agilent Technologies) used in this study con-
tained 45015 oligonucleotide probes covering the entire
human transcriptome. cRNA-synthesis was performed
with the “Low RNA Input Linear Amplification Kit PLUS,
Two-Color” (#5188-5340, Agilent Technologies) as direc-
ted by the manufacturer. cRNA fragmentation, hybridiza-
tion and washing steps were also performed exactly as
recommended by the manufacturer “Two-Color Microar-
ray-Based Gene Expression Analysis Protocol V5.5” (see
http://www.agilent.com for details) except that 4 μgo f
each labeled cRNA were used for hybridization. Slides
were scanned on the Agilent Micro Array Scanner G2505
B at two different PMT settings, namely 100% (default set-
ting) and 5%, to increase the dynamic range of the mea-
surements. Data extraction and normalization were
performed with the “Feature Extraction Software V9.5.3.1”
by using the recommended default extraction protocol file:
GE2-v5_95_Feb07.xml. Only probes with allocated gene
symbols and arithmetic mean intensity >50 for both chan-
nels were considered for further analysis. Genes with
p value ≤ 0.0001 and fold induction ratio of ≥ 2 were con-
sidered significantly induced.
Accession Numbers
The complete microarray data have been deposited in
NCBI’s Gene Expression Omnibus and are accessible
through GEO series accession number GSE28045.
Functional and gene ontology analysis
Categorization of genes according to protein class was
done using PANTHER (Protein Analysis Through Evo-
lutionary Relationships) Classification Systems [32]. For
each protein class, PANTHER calculates the number of
genes identified in that category in both the list of dif-
ferentially regulated genes and a reference list contain-
ing all the probe sets present on the chip and compares
these results using the binomial test to determine if
there are more genes than expected in the differentially
regulated list [33]. Over-representation is defined by p <
0.05. Functional Analysis identifying the biological func-
tions that were most significant to the data set were car-
ried out using Ingenuity Pathways Analysis (IPA)
(Ingenuity Systems, Mountain View, CA). Right-tailed
Fisher’s exact test was used to calculate a p-value deter-
mining the probability that each biological function and/
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alone.
RT-PCR and qRT-PCR
Reverse transcription was carried out using oligo dT pri-
mers and the Omniscript reverse transcriptase kit (Qiagen)
following the instructions provided. PCRs were set up
according to the following profile: an initial denaturation
step of 94°C for 2 min, repeating cycles of 94°C for 30 sec-
onds, annealing temperature given for each primer pair for
1 minute, and 72°C for 1 minute. Following primer pairs
were used: human EGR-1 (NM_001964) forward primer:
5’-CAGCAGTCCCATTTACTCAG-3’, reverse primer: 5’-
GACTGGTAGCTGGTATTG-3’ (annealing temperature
56°C, product size 345 bp); human KLF2 (NM_016270)
forward primer: 5’-CTACACCAAGAGTTCGCATCTG-
3’, reverse primer: 5’-CCGTGTGCTTTCGGTAGTG-
3’(annealing temperature 57°C, product size 137 bp);
human SMAD7 (NM_005904) forward primer: 5’-ACTC-
CAGATACCCGATGGATTT-3’, reverse primer: 5’-
CCTCCCAGTATGCCACCAC-3’ (annealing temperature
57°C, product size 174 bp); human beta-actin (ACTB,
NM_001101) forward primer: 5’-CCCAAGGCCAAC
CGCGAGAAGAT-3’, reverse primer: 5’-GTCCCGGCC
AGCCAGGTCCAG-3’ (annealing temperature 66°C, pro-
duct size 219 bp). Separation of the DNA fragments was
carried out on 2% (w/v) agarose gels, stained with ethi-
dium bromide (2 μg/ml) and photographed under UV
light. Quantitative (TaqMan) RT-PCR was performed as
previously described [40]. TaqMan probes (Applied Bio-
systems, assay-IDs as follows: Hs00152928_m1(EGR1);
Hs00357891_s1(JUNB); Hs00170630_m1(FOS); Hs001
53408_m1(MYC); Hs00360439_g1(KLF2); Hs99999
905_m1(GAPDH); Hs99999908_m1(GUSB)) were used
with TaqMan
® Fast Universal PCR Master Mix (2×)
(Applied Biosystems).
Transfection, RNA interference and immunoblotting
SiRNA against human LKLF (KLF2) and control siRNA
was purchased from Santa Cruz Biotechnology (Santa
C r u z ,C A ) .4×1 0
6 HMC-1(V560G c-Kit) cells were
transfected with 200 pmol of siRNA using Amaxa
® Cell
Line Nucleofector Kit L with program T-020 in an
Amaxa
® Nucleofector
® II device according to the manu-
facturer’s instructions. Two days after transfection, cells
were treated with imatinib (5 μM) for up to 15 h.
During imatinib treatment, aliquots were prepared for
analysis by TUNEL staining or immunoblot.
For immunoblot analysis, whole cell lysates were pre-
pared using 1 × SDS buffer (80 mM Tris/HCl, pH 6.8,
2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% beta-
mercaptoethanol, 0.01% bromphenole blue). Then, cell
lysates were analyzed for cleavage fragments of caspase
3 by immunoblot analysis using a polyclonal antibody
against cleaved caspase-3 (Asp175) (Cell Signaling Tech-
nology, Beverly, MA) or GAPDH (Santa Cruz Biotech-
nology) as described previously [15]. Knockdown of
KLF2 was verified by semi-quantitative RT-PCR and
quantitative analysis was performed using TINA2.0 soft-
ware (Raytest Isotopenmessgeraete GmbH, Strauben-
hardt, Germany).
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